“Veeva enables us to unify quality management for greater end-to-end control of quality manufacturing around the world,” said James Choi, senior vice president and chief information officer, Samsung Biologics. “With a modern technology foundation, we can deliver value-added services that help our customers stay ahead of changing business and regulatory requirements.”
Samsung Biologics provides development, manufacturing, and laboratory testing services across the product lifecycle. The CDMO required a scalable system that would provide internal and external stakeholders with transparency into enterprise quality and document management processes.
Vault QMS is a modern cloud application that unifies quality management and easily incorporates Samsung Biologics’ internal organization, pharmaceutical and biotech customers, contract manufacturers, and suppliers into one quality process. This allows Samsung Biologics to better align its global processes for greater visibility and compliance throughout the product lifecycle.
“Samsung Biologics is an innovative company that is leading the way in modernizing quality manufacturing,” said Chris Shim, vice president R&D Asia, Veeva. “We’re excited to expand our partnership with Samsung Biologics and support their strategy to harmonize quality processes and meet the evolving needs of the global healthcare industry.”